Heartcore Capital

Teitur Trophics is a biotech company based in Aarhus, Denmark, established in 2020. The company focuses on developing circular peptides aimed at addressing neurodegenerative diseases. By studying small peptides that interact with receptors crucial for neural function, Teitur Trophics aims to understand the underlying biology and modulate key mechanisms involved in neural activity. This research is intended to support healthcare professionals in creating treatments that can prevent the onset of neurodegenerative conditions through daily injections.

Ascelia Pharma is a biotechnology company based in Malmö, Sweden, specializing in drug development for orphan oncology treatments. The company is dedicated to addressing unmet medical needs in the oncology sector by developing and commercializing innovative therapies. Ascelia Pharma has two drug candidates currently in clinical development: Orviglance and Oncoral. These candidates are designed to provide new options for patients with specific cancer types, reflecting the company's commitment to improving outcomes in underserved patient populations.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Fast Travel Games is a game development studio based in Stockholm, Sweden, specializing in virtual reality (VR) games. Founded by experienced professionals from notable studios such as EA DICE, Rovio, and Avalanche, the company aims to transform the gaming experience through immersive VR environments. They focus on creating games that promote exploration, rich narratives, and social interaction, allowing players to engage with their surroundings and each other in innovative ways. Fast Travel Games is dedicated to delivering engaging experiences that enhance the way players connect with gaming universes.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

Neo4j, Inc. develops a graph database platform that helps organizations understand and leverage the connections between people, processes, locations, and systems. This platform is utilized in various applications, including artificial intelligence, analytics, fraud detection, identity management, knowledge graphs, and recommendation engines. It enables developers and data scientists to build intelligent applications and machine learning workflows effectively. Neo4j offers its services as a fully managed cloud solution or as a self-hosted option, catering to clients across multiple sectors such as financial services, retail, government, and telecommunications. Founded in 2007 and headquartered in San Mateo, California, Neo4j also has offices in Sweden, the United Kingdom, and France.

Fast Travel Games is a game development studio based in Stockholm, Sweden, specializing in virtual reality (VR) games. Founded by experienced professionals from notable studios such as EA DICE, Rovio, and Avalanche, the company aims to transform the gaming experience through immersive VR environments. They focus on creating games that promote exploration, rich narratives, and social interaction, allowing players to engage with their surroundings and each other in innovative ways. Fast Travel Games is dedicated to delivering engaging experiences that enhance the way players connect with gaming universes.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

Boozt is an e-commerce company based in Malmö, Sweden, specializing in fashion, apparel, and beauty products for the Nordic market. It operates two main webshops: Boozt.com and Booztlet.com. Boozt.com serves as a multi-brand online destination offering a curated selection of products across various categories, including fashion, kids, sports, beauty, and home. In contrast, Booztlet.com focuses on inventory clearance, retailing items that have not sold within their designated timeframe on Boozt.com. The company collaborates with high-profile brands such as ECCO, Jack&Jones, and Vero Moda, among others, and employs 45 staff members in Sweden, supplemented by 30 offshore resources in Vietnam and India. Through its platforms, Boozt aims to provide convenience and a diverse range of products to customers in Northern Europe.

Ministry of Games is a mobile game development studio that designs and develops games focused on experience. It aims to bring RPGs to mobile platforms. The company is backed by Initial Capital, Index Ventures, Sunstone Capital, Proxy Ventures, Henric Suuronen, Markus Pasula, and Tekes. Ministry of Games was founded in 2014 and is based in Helsinki, Finland.

Neo4j, Inc. develops a graph database platform that helps organizations understand and leverage the connections between people, processes, locations, and systems. This platform is utilized in various applications, including artificial intelligence, analytics, fraud detection, identity management, knowledge graphs, and recommendation engines. It enables developers and data scientists to build intelligent applications and machine learning workflows effectively. Neo4j offers its services as a fully managed cloud solution or as a self-hosted option, catering to clients across multiple sectors such as financial services, retail, government, and telecommunications. Founded in 2007 and headquartered in San Mateo, California, Neo4j also has offices in Sweden, the United Kingdom, and France.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Traplight creates ultra approachable and deep F2P games. From the first seconds their games offer you fun, effortless gameplay and a deep, empowering progression. They focus on creating entertainment that lasts for years and is always fresh. Players are the ones they create their games for, not us. This drives us to make fun, empowering and coherent gaming experiences that their players truly want. Founded in 2010 and based in Tampere, Finland, Traplight currently has a 28 strong team working on several games. Traplight’s team and vision have been backed up by renowned game investors such as Initial Capital, Korea Investment Partners, Sunstone Capital and Finnvera Venture Capital. Traplight’s Big Bang Racing was chosen as Best of 2016 in AppStore, and currently the company is preparing to soft launch their next big hit soon.

Pulmologix AB is a Swedish private clinical stage company founded in 2006 and based in Stockholm. The company focuses on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug specifically for the treatment of early onset allergic asthma. Pulmologix is dedicated to exploring innovative medical approaches to address respiratory diseases, contributing to advancements in asthma treatment.

Tink is a cloud-based open banking platform that provides the infrastructure and value-adding data products that are enabling the future of financial services. Tink offers products such as account aggregation, payment initiation, data enrichment, and personal finance management that can be used to develop standalone services or be integrated into existing banking applications. Its partners include ABN AMRO, BNP Paribas Fortis, Nordea, Klarna, and SEB. Tink was founded in 2012 and is based in Stockholm, Sweden.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.

Templafy ApS, founded in 2013 and based in Copenhagen, Denmark, provides a comprehensive platform for template and document management solutions. The company specializes in automating business document creation, enabling organizations to produce compliant and on-brand documents efficiently. Its offerings include dynamic personalization, document automation, brand validation, and template governance services. Templafy’s platform integrates seamlessly with existing software, such as Microsoft Office and Salesforce, allowing users to access company templates and streamline content workflows. Catering to various industries, including banking, consulting, education, and legal services, Templafy supports millions of users across over 800 enterprise customers globally. The company has raised significant funding from leading investors to further enhance its innovative document generation capabilities.

FBC Device ApS, founded in 2005 and based in Risskov, Denmark, specializes in the manufacture and marketing of spinal fusion implants. The company achieved its first significant milestone in 2013 when its Statur product line received the CE mark, allowing it to enter the European and Canadian markets. FBC Device has also obtained ISO 13485 certification, reflecting its commitment to high-quality standards. Its innovative two-piece anterior interbody fusion implant incorporates tantalum spheres as radiologic markers, enabling surgeons to adjust lordosis during procedures. This technology aims to improve patient outcomes by offering a self-adapting ALIF cage that positively influences sagittal balance. The company holds patents in Europe and the United States, further solidifying its position in the spinal implant industry.

Mofibo started in Copenhagen (2013) as one of the world’s first book subscription services. We are currently in three countries and will be expanding into more countries within the next 12 months. Our overall goal is to transform the way millions of people interact with books, through using a data-driven and customer centric approach to fundamentally change the reading experience crosses multiple countries.

Neo4j, Inc. develops a graph database platform that helps organizations understand and leverage the connections between people, processes, locations, and systems. This platform is utilized in various applications, including artificial intelligence, analytics, fraud detection, identity management, knowledge graphs, and recommendation engines. It enables developers and data scientists to build intelligent applications and machine learning workflows effectively. Neo4j offers its services as a fully managed cloud solution or as a self-hosted option, catering to clients across multiple sectors such as financial services, retail, government, and telecommunications. Founded in 2007 and headquartered in San Mateo, California, Neo4j also has offices in Sweden, the United Kingdom, and France.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.

Neo4j, Inc. develops a graph database platform that helps organizations understand and leverage the connections between people, processes, locations, and systems. This platform is utilized in various applications, including artificial intelligence, analytics, fraud detection, identity management, knowledge graphs, and recommendation engines. It enables developers and data scientists to build intelligent applications and machine learning workflows effectively. Neo4j offers its services as a fully managed cloud solution or as a self-hosted option, catering to clients across multiple sectors such as financial services, retail, government, and telecommunications. Founded in 2007 and headquartered in San Mateo, California, Neo4j also has offices in Sweden, the United Kingdom, and France.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

Podio, a collaborative work platform now part of Citrix, offers a unique approach to managing everyday work. It empowers users to customize their work environments by integrating various specialized applications with features such as messaging, task management, reporting, workflow, and contact management. This versatility allows teams to streamline their processes and unify their work activities within a single platform, eliminating the need for multiple tools and logins. Based in Copenhagen, Podio serves a diverse range of teams and organizations globally, providing them with the resources to enhance productivity and collaboration. The company is led by CEO Tommy Ahlers and has a board chaired by Thomas Madsen-Mygdal, with a multinational team that includes members from Germany, France, Britain, and Denmark.

Acarix A/S is a medical technology company specializing in innovative solutions for the rapid exclusion of coronary artery disease (CAD). Established in 2009 as a spin-out from Coloplast A/S, Acarix is rooted in pioneering research initiated at Aalborg University in Denmark. The company has developed the CE-marked CADScor System, which has also received DeNovo approval from the FDA. This system is designed for patients experiencing chest pain with suspected CAD and aims to minimize unnecessary and costly invasive diagnostic procedures. Utilizing advanced acoustics and artificial intelligence, the CADScor System can non-invasively rule out CAD in under 10 minutes, achieving a certainty rate of at least 96 percent. Acarix continues to focus on enhancing patient care and streamlining diagnostic processes in cardiology.

Action Pharma A/S is a biotechnology company focused on research and development, specializing in the discovery and development of novel drugs for cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company aims to create treatment options for conditions such as type-II diabetes, obesity, kidney injury related to cardiac surgery, inflammatory bowel disease, rheumatoid arthritis, and inflammatory skin diseases like atopic dermatitis. Its product pipeline includes AP214, a modified MSH peptide analogue for post-surgical kidney injury; AP1030 and AP11 series, oral medications for type-II diabetes; AP1189, an anti-inflammatory compound for various inflammatory diseases; and AP405, another modified MSH peptide aimed at treating inflammatory skin conditions. Action Pharma's approach focuses on targeting melanocortin receptors, progressing its candidates toward clinical proof of concept to facilitate future partnerships.

Neo4j, Inc. develops a graph database platform that helps organizations understand and leverage the connections between people, processes, locations, and systems. This platform is utilized in various applications, including artificial intelligence, analytics, fraud detection, identity management, knowledge graphs, and recommendation engines. It enables developers and data scientists to build intelligent applications and machine learning workflows effectively. Neo4j offers its services as a fully managed cloud solution or as a self-hosted option, catering to clients across multiple sectors such as financial services, retail, government, and telecommunications. Founded in 2007 and headquartered in San Mateo, California, Neo4j also has offices in Sweden, the United Kingdom, and France.

Action Pharma A/S is a biotechnology company focused on research and development, specializing in the discovery and development of novel drugs for cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company aims to create treatment options for conditions such as type-II diabetes, obesity, kidney injury related to cardiac surgery, inflammatory bowel disease, rheumatoid arthritis, and inflammatory skin diseases like atopic dermatitis. Its product pipeline includes AP214, a modified MSH peptide analogue for post-surgical kidney injury; AP1030 and AP11 series, oral medications for type-II diabetes; AP1189, an anti-inflammatory compound for various inflammatory diseases; and AP405, another modified MSH peptide aimed at treating inflammatory skin conditions. Action Pharma's approach focuses on targeting melanocortin receptors, progressing its candidates toward clinical proof of concept to facilitate future partnerships.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Issuu, Inc. is a digital publishing and discovery platform founded in 2006, with headquarters in Palo Alto, California, and additional offices in Berlin and Copenhagen. The company offers a comprehensive suite of tools for digital publishing, allowing users to create and share a variety of content, including magazines, newspapers, catalogs, and portfolios. With a focus on enhancing the reader experience, Issuu supports over 17 million publications and serves more than 80 million active readers each month. The platform enables publishers, both large and small, to easily upload and distribute their work while maintaining the visual appeal associated with print media. Moreover, Issuu provides various features, such as custom viewer themes, API integrations, and monetization solutions, which facilitate seamless publication management and audience engagement across devices and social networks.